Aakash R Sheth, MD

Thank you @CureNETs @greeneannac for the opportunity to write this guest blog post for updates in Neuroendocrine Cancer research presented at #ASCO26 Link- netrf.org/2026/06/18/grewal-… 1️⃣ Alpha RLT- Early phase data with ²¹²Pb-VMT-α-NET showed a 39% ORR with minimal marrow/renal toxicity, reinforcing the promise of alpha-emitting radioligand therapy. @OncoThor 2️⃣ DLL3 (the target we're all excited about in high grade NENs)- The trispecific T-cell engager alveltamig (ZG006) achieved up to 56% ORR in DLL3-high refractory NEC. Excited to see this moving along. 3️⃣ CAR-T enters the NET space!! Early feasibility data with CDH17-directed CAR-T (CHM-2101) showed successful manufacturing, expansion, and manageable toxicity in GI cancers including intestinal NETs. (Dr Jen Eads @UPennCancer )- trial also open @WinshipAtEmory 4️⃣ MTAP loss in NETs!!?? Unexpectedly high MTAP deficiency across PanNETs and small bowel NETs, reported by @rohit_thum. Room for PRMT5i/MAT2Ai in NETs? 5️⃣ Long-term PRRT safety data matter — In >1,800 patients treated with Lu-177 DOTATATE, overall risk for therapy-related MDS/AML remained low (2.9%) but there is a genuine need for better risk stratification. @deevyaparekh @NANETS1 @lisayentwin @TheGutOncLab

Re-sharing our commentary on the struggles of FMGs training on J1 visas. About time we addressed the need for extended J1 visas (covering the duration of training) and fair employment opportunities. This IS a part of physician well-being! 🇺🇸 🌎 Link👉🏽 link.springer.com/article/10…